In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara Inc (NASDAQ: SVRA), with a price target of $22. The company’s shares closed yesterday at $11.52.
Fein wrote:
“Valuation and risks to achievement of target price. Our price target of $22/share is based on an equally weighted composite of: (a) $20/share, as a 30x multiple of taxed and diluted $5.02 discounted back to FY18 at 25% (in line with the expected PE multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $23/share (discounted cash flow analysis using a 12% discount rate and 1.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.6% and a 46.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara Inc with a $29 average price target, which is a 151.7% upside from current levels. In a report issued on August 2, Canaccord Genuity also maintained a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.19 and a one-year low of $5.07. Currently, Savara Inc has an average volume of 274.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
